Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer
Conditions: Hormone Sensitive Prostate Cancer; Prostate Adenocarcinoma; Metastasis Prostate Adenocarcinoma Interventions: Drug: Androgen Deprivation Therapy; Drug: Nivolumab; Drug: Docetaxel Sponsors: Xiao X. Wei; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Docetaxel | Hormones | Prostate Cancer | Research | Taxotere